UK Committee Rejects Mass Prostate Screening, BRCA2
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UKNSC released its final recommendation that widespread PSA testing is “likely to cause more harm than good”.
- BRCA2‑carrier men with a family history of breast, ovarian, pancreatic or prostate cancers should be screened every two years between ages 45 and 61.
- Black men were advised against routine screening, with the committee noting “ongoing uncertainty” about net benefit.
- Mike Richards warned that overdiagnosis remains high and that prostate cancer treatments can cause lasting incontinence and erectile dysfunction.
- The recommendation is projected to result in “a few thousand” men being screened annually, limited to the BRCA2‑identified group.
- James Murray will receive the recommendation for government consideration, with a meeting scheduled with Mike Richards.
Why it matters: The UK’s rejection of mass prostate screening spares most men from potential overdiagnosis and treatment‑related harms, but also denies them early detection benefits; it directs limited resources to BRCA2‑carrier men, while advocacy groups lose a broader screening push, and the health secretary must decide on implementation.
